Navigation Links
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Date:4/16/2008

NEW YORK, April 16 /PRNewswire/ -- NexGenix Pharmaceuticals, presented data on its Hsp90 inhibitor program today at the Annual Meeting of the AACR in San Diego today. The company presented data in the experimental therapeutics session on NXD30001, one of several novel, radicicol-based Hsp90 inhibitors in its compound series.

NXD30001 demonstrated efficacy in breast cancer tumor xenograft models without evidence for liver and kidney toxicity. The potency, tolerability, pharmacokinetic and pharmacodynamic properties of NXD30001 and its derivatives indicate that it, or an analog, may be useful in the treatment of breast and other forms of cancer with an improved dosing and therapeutic window compared to 17AAG, the first-in-class Hsp90 inhibitor currently in Phase 2 clinical trials for cancer.

The compound series appears to bind Hsp90 in a different mode than 17AAG or radicicol and exhibit higher affinity to Hsp90 than radicicol. NXD30001 and its analogs efficiently inhibit cell proliferation and deplete multiple Hsp90 client proteins such as Her2, Akt, c-Raf, Cdk4, and Cyclin D1 in Her2-overexpressing breast and other cancer cell lines at low nanomolar concentrations. Pharmacokinetic studies demonstrate that NXD30001 can achieve potential therapeutic levels via intraperitoneal (i.p.) dosing and that the compound accumulates in tumors at above micromolar concentrations.

Tumor pharmacodynamic analysis demonstrated depletion of multiple Hsp90 client proteins, including Her2, after a single dose; these client proteins remained undetectable for more than 2 days, consistent with the pharmacokinetic tumor data.

"A number of analogs with activity similar to or better than NXD30001 have been synthesized and are being evaluated for oral bioavailability, tolerability, and efficacy," stated Allan Rubenstein, MD, CEO of NexGenix. "Our intent is to progress an i.v. formulation of NXD30001 into IND-enabling studies for breast cancer, and to develop
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Toronto, Canada (PRWEB) July 10, 2014 ... often present in very low abundance and are ... quite challenging and time-consuming. , Join presenters Dr. ... Laboratories, and Dr. John Anders, Head of Quality ... mass spectrometer-based approach that can speed detection and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... WASHINGTON , May 20 Today, world-renowned ... and his team at the J. Craig Venter Institute (JCVI) ... self-replicating cell.  The news holds groundbreaking potential for solutions to ... pharmaceuticals and vaccines; cleaning up pollution; creating new energy sources; ...
... ... University of California campuses -- San Francisco and Berkeley -- to jointly launch the first ... patient care. , ... 20, 2010 -- Former Intel Corp. chief executive Andy Grove has pledged $1.5 million to ...
... SAN FRANCISCO and WASHINGTON , ... Inc., a clinical-stage cancer biotherapeutics company, today reported positive ... the intravenous (IV) administration of JX-594 to patients with ... delivery to solid tumors, cancer-targeted replication and gene expression, ...
Cached Biology Technology:Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 2Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 3Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 2Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 3Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 4Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 2Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 3Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 4
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... develop relationships with other group members to reduce aggression ... baboons the strategy for grooming activities shows a certain ... in the scientific journal Biology Letters . , ... not practiced without ulterior motives. To be groomed has ... while grooming another individual can provide access to infants, ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... can complicate treatment after many surgical procedures. In ... found in many healthcare settings, can be a ... the April issue of the American Journal of ... of 12 patients after refractive surgery. , These ...
... to weigh less than children who sleep less, and ... overweight five years later. That’s one of the major ... 2007 issue of the journal Child Development. , Conducted ... 2,281 children from a nationally representative survey called the ...
... $22.5 million research program at Iowa State University ... The grant is part of ConocoPhillips' plan to ... produce viable solutions to diversify America's energy sources. ... million grant in 2007 to support Iowa State ...
Cached Biology News:Drug-resistant bacterial infections serious complication after corrective eye surgery 2Children who sleep more weigh less 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 3
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
... kit consists of universal lysis buffer, PCR ... for 100 25 l volume PCR reactions. ... Gram negative or positive rod and coccus ... Bacillus Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and ...
... The SilverQuest Silver Staining Kit ... silver staining sensitivity with minimal protein ... The mass spectrometry problems associated with ... the SilverQuest kit because the reagents ...
...
Biology Products: